论文部分内容阅读
目的:研究抗氧化剂硫普罗宁对晚期非小细胞肺癌化疗的影响。方法:筛选江苏省肿瘤医院化疗科2004年6月～2007年12月的患者病例资料。在一线化疗过程中合并使用硫普罗宁的晚期非小细胞肺癌病例为硫普罗宁联合化疗组(A组),并随机选择同等数目的未合并使用硫普罗宁的晚期非小细胞肺癌一线化疗患者为对照组(B组)。运用Stata8.0统计软件分析比较两组间化疗的疗效、不良反应及生存情况。结果:总计246例病例纳入研究。A组和B组化疗有效率分别为22.0%和19.5%,临床获益率分别为78.9%和74.0%,差异均无统计学意义(P>0.05);白细胞降低发生率分别为41.5%和54.4%(P=0.041),差异有统计学意义;A组和B组的中位生存时间分别为11.8[95%可信区间(confidence interval,CI):10.2～13.8]个月和9.8(95%CI:8.7～11.3)个月,中位疾病无进展时间分别为6.2(95%CI:4.4～8.2)个月和4.5(95%CI:4.2～6.4)个月,差异均无统计学意义(P>0.05);一年生存率分别为48.8%和35.8%(P=0.028),差异有统计学意义。结论:在晚期非小细胞肺癌一线化疗中合并使用抗氧化剂硫普罗宁虽未明显提高化疗近期疗效及延长生存时间,但可减轻化疗所致白细胞降低并提高一年生存率。
Objective: To study the effect of anti-oxidant tiopronin on chemotherapy of advanced non-small cell lung cancer. Methods: The data of patients in Jiangsu Cancer Hospital Chemotherapy Unit from June 2004 to December 2007 were screened. In the first-line chemotherapy combined with the application of tiopronin in advanced non-small cell lung cancer cases of tiopronin combined with chemotherapy (group A), and were randomly selected an equal number of non-combined use of tiopronin advanced non-small cell lung cancer patients with first-line chemotherapy For the control group (group B). Stata8.0 statistical software analysis and comparison between the two groups of chemotherapy efficacy, adverse reactions and survival. Results: A total of 246 cases were included in the study. The effective rates of chemotherapy in group A and group B were 22.0% and 19.5% respectively, and the clinical benefit rates were 78.9% and 74.0% respectively, with no significant difference (P> 0.05). The incidences of leukopenia were 41.5% and 54.4% respectively % (P = 0.041), the difference was statistically significant. The median survival time in group A and group B were 11.8 [95% confidence interval (CI): 10.2-13.8] months and 9.8 CI: 8.7-11.3) months, median progression-free time was 6.2 (95% CI: 4.4-8.2) and 4.5 (95% CI: 4.2-6.4) months, respectively, with no significant difference P> 0.05). The one-year survival rates were 48.8% and 35.8%, respectively (P = 0.028), the difference was statistically significant. Conclusion: The combination of anti-oxidant tiopronin in the first-line chemotherapy for advanced non-small cell lung cancer did not significantly improve the curative effect and prolong the survival time of chemotherapy, but could reduce the chemotherapy-induced leukopenia and increase the one-year survival rate.